InsiderTrades

Form 4 for CLDX Celldex Therapeutics, Inc.

Accepted 2024-06-03 00:00:00 ET · period of report 2024-05-30 · accession 0001415889-24-015137 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-06-03 2024-05-30 CLDX Crowley Elizabeth SVP, CPDO M - OptEx $4.02 +42.9K 39.2K New +$172.4K
D 2024-06-03 2024-05-30 CLDX Crowley Elizabeth SVP, CPDO S - Sale+OE $33.64 -38.6K 9,074 -81% -$1.30M
DM 2024-06-03 2024-05-30 CLDX Crowley Elizabeth SVP, CPDO M - OptEx $0.00 -42.9K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-05-30 M A 8,500 $9.02 47,671 D — —
2 Common Common Stock 2024-05-30 M A 34,445 $2.78 39,171 D — —
3 Common Common Stock 2024-05-30 S D 38,597 $33.64 9,074 D — — (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.39 to $33.8934 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
4 Derivative Incentive Stock Option (Right to Buy) 2024-05-30 M D 8,500 $0.00 7,500 D $9.02 · — to 2028-06-13 8,500 Common Stock (F3) As of June 13, 2022, the option is fully vested.
5 Derivative Incentive Stock Option (Right to Buy) 2024-05-30 M D 34,445 $0.00 0 D $2.78 · — to 2029-06-19 34,445 Common Stock (F2) As of June 19, 2023, the option is fully vested.